NCT00103922
Completed
Phase 3
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Overview
- Phase
- Phase 3
- Intervention
- cilomilast
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Sponsor
- GlaxoSmithKline
- Enrollment
- 600
- Locations
- 1
- Primary Endpoint
- measure of lung function and quality of life in patients with COPD
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Arm 1
Intervention: cilomilast
Outcomes
Primary Outcomes
measure of lung function and quality of life in patients with COPD
Secondary Outcomes
- exacerbations in patients with COPD
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.AsthmaNCT00600171GlaxoSmithKline614
Completed
Phase 2
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.AsthmaNCT00398645GlaxoSmithKline648
Completed
Phase 2
Study Evaluating ERB-041 in Endometriosis in Reproductive-Age WomenEndometriosisNCT00110487Wyeth is now a wholly owned subsidiary of Pfizer200
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B VaccineHepatitis B, ChronicNCT04289987CHA Vaccine Institute Co., Ltd.134
Completed
Phase 2
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.AsthmaNCT00603382GlaxoSmithKline599